成片一卡三卡四卡免费网站,色婷婷五月天,一日本道伊人久久综合影,XXXX张怕芝XXXXXBBBBB

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

乱子伦XXX 无码69 | 国产成人精品免费视频 | 国产精品一区二区无线 | 欧美亚洲刺激视频 | 樱桃成人精品永久免费AV | 东北老妇性猛交XXⅩXX | 亲亲草成人VA视屏 | 国产人妻麻豆一区二区 | 亚洲日韩在线欧美A | 18黄色视频网站 | 亚洲高清无码在线 | 国产爆乳美女娇喘呻吟色欲 | 亚洲日本三级片在线观看 | 久久久91人妻无码精品蜜桃 | 欧美日韩台色视频在线播放 | 中日韩美女体内射精 | 久久久久久精久久ww | 成人片毛片A片免费网站小说 | 真实农村女人偷人视频 | 农村婬乱男女A片爽视频麻豆软件 | 911A片成人久久影院 | 色噜噜人妻丝袜a∨先锋影 国产AV一区二区三区精品 | 三级片免费欧洲中文 | 日本熟妇搡BBBB搡BBB | 成人AV免费在线 | 中文字幕在线免费视频 | 亚洲熟妇偷人无码精品 | 人伦人与牲囗恔配视频 | 精品一级片内射免费观看 | 欧美精品久久久久久 | 肥婆多水一级毛片免费 | 精品91秘 一区二区三区 | 91黄色视频免费看 | 国产成人av一级在线观看 | 国内外久久成人色免费视频 | 久久精品在线观看 | 又大又粗又硬又爽又黄毛片视频 | 国产一区亚洲二区在线观看 | 婷婷蜜桃97香蕉 | 蜜桃AV鲁一鲁一鲁一鲁俄罗斯的 | 久久天天躁狠狠躁夜夜av |